Abstract
The intention of this study was to identify the pretreatment characteristics predicting for the survival, objective response and symptom relief in patients with non-resectable, non-small-cell lung cancer (NSCLC) managed in the Lung Unit at the Royal Marsden Hospital. This analysis included 290 patients with advanced NSCLC generally treated with a cisplatin-based chemotherapy regimen in one of a series of trials. Thirty-seven pretreatment variables, response and survival data were collected prospectively and analysed using univariate and multivariate methods. By multivariate analysis performance status, disease extent and pattern of metastases along with certain biochemical features were influential independent variables for survival, objective and symptom response. Older age was positively associated with objective response (P = 0.04). When the independent factors for symptom response were used to group patients into prognostic categories, 30-48% of patients with an adverse set of factors had symptom relief. Similarly using the relative risk of death to subgroup the patient population, 54% of patients at high risk of death (greater than 8.0), with a median survival of 2.5 months, had symptom relief. The data are consistent with other studies in identifying the pretreatment factors predicting for survival and objective response. Additionally, older age is positively associated with objective response and the majority of patients with the worst prognosis have symptom relief from treatment with chemotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hickish, T., Smith, I., O'Brien, M. et al. Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors. Br J Cancer 78, 28–33 (1998). https://doi.org/10.1038/bjc.1998.437
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.437
This article is cited by
-
First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly
Current Oncology Reports (2021)
-
Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer
Current Treatment Options in Oncology (2016)
-
Quality of life during chemotherapy in lung cancer patients: results across different treatment lines
British Journal of Cancer (2013)
-
Treatment Outcomes in Elderly with Advanced-Stage Non-small Cell Lung Cancer
Lung (2013)
-
Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer
Cancer Chemotherapy and Pharmacology (2009)